AirAvant Medical is a research-oriented, privately held company based in the U.S. that focuses on developing and marketing innovative respiratory medical devices to treat obstructive sleep apnea and other breathing disorders. AirAvant has launched the Bongo® Rx, a groundbreaking EPAP device that is FDA-cleared to treat mild to moderate obstructive sleep apnea.
Holding numerous patents with several patents pending, AirAvant Medical continues to innovate revolutionary respiratory technologies for the sleep-disorder breathing market, which includes Obstructive Sleep Apnea, snoring, and COPD applications.
AirAvant Medical was founded by Bruce Sher, Shara Hernandez, Javier Collazo, and Ron Richard. The company’s founders were former executives at InnoMed Technologies, Inc., where they had developed and launched a highly acclaimed line of respiratory and sleep devices, including the Nasal-Aire, the Hybrid, and the Aloha CPAP interfaces. In 2019, AirAvant Medical introduced its flagship product – the Bongo Rx.
AirAvant Medical’s mission is to improve health and welfare by creating user-centered, non-surgical medical devices that treat respiratory disorders while minimizing impact to the patient’s lifestyle.
With the Bongo Rx, AirAvant Medical aims to transform the sleep apnea market by meeting the need for a more discreet and less encumbering solution than other therapies commonly prescribed today.
Our company will continue developing cutting-edge respiratory medical devices to meet the demand for user-friendly design and effective treatment in the sleep-disorder breathing market. AirAvant Medical is committed to delivering innovative products, high product quality, and excellent customer service.
Meet The Founders
Co-Founder | Co-President
Co-Founder | Co-President
Co-Founder | Vice-President | General Manager
Meet The Medical Technology Advisory Committee
Jerrold Kram, MD, FAASM
Medical Director at California Center for Sleep Disorders Alameda, CA
Alan Lankford, PhD, FAASM
Sleep Medicine Clinician/Scientist, Director of Research at The Neurological Center of North Georgia and Chief Science Officer at SleepSafe Drivers
Rafael Pelayo, MD, FAASM
Clinical Professor, Sleep Medicine Division at Stanford University School of Medicine and 2020 President-elect at California Sleep Society
Lynn M. Schmidt, PhD, RN, CNE
Dean, Nursing & Kinesiology at Anderson University
Why The Bongo Rx Was Developed
A Treatment for Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) affects approximately 30 million people in the U.S. alone. Some studies suggest that approximately 50% of patients stop using their CPAP machine, the predominant treatment for OSA, citing noise, discomfort, claustrophobia, inconvenience, and cost.
AirAvant Medical conceived the Bongo Rx as a discreet and user-friendly EPAP device to treat sleep apnea. AirAvant Medical (a DBA of InnoMed Healthscience) is registered with the U.S. Food and Drug Administration and its Bongo Rx has received FDA 510(k) Clearance for the treatment of mild to moderate obstructive sleep apnea (OSA).
An Alternative to CPAP Therapy
In most OSA cases today, CPAP treatment is prescribed by health professionals, and patients have very few other options. CPAP is a proven effective treatment for patients who can tolerate it; however, it involves a significant lifestyle adjustment.
Patients must cope with a strenuous breathing experience, bedside nuisance of the electronic equipment, obtrusive hoses, and bulky masks. Many patients ultimately find that they cannot adapt to CPAP and subsequently give up on treatment.
AirAvant believes that its Bongo Rx EPAP device provides patients and providers with a viable non-surgical CPAP alternative, for cases where either (a) CPAP is not an effective option due to non-compliance or (b) the patient is seeking a treatment that is more convenient and less obtrusive than CPAP.
A Game-Changing Respiratory Medical Device